A201 EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES

Simon Travis, T Hibi, Tadakazu Hisamatsu, Deborah L. Fisher, Mingyang Shan, Theresa Hunter, Donald B. Rubin, Jennifer JonesJournal of the Canadian Association of Gastroenterology 2023 · DOI

TL;DR

This study demonstrates that mirikizumab (miri) significantly improves bowel urgency, a highly disruptive symptom of ulcerative colitis (UC), in both induction and maintenance phases of treatment. The Urgency Numeric Rating Scale (UNRS) proved effective in quantifying these improvements, showing clinically meaningful changes and remission rates for miri-treated patients compared to placebo.

What Problem Does This Paper Address?

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by symptoms like diarrhea, rectal bleeding, and abdominal pain. However, bowel urgency (BU) – a sudden, compelling need to defecate – is often a particularly debilitating and disruptive symptom that significantly impacts patients' quality of life, even when other UC symptoms are managed. While treatments exist for UC, their efficacy in specifically addressing bowel urgency has been a key area of investigation. This paper addresses the need to quantify the impact of mirikizumab, a novel biologic therapy, on this specific, troublesome symptom.

Methods

The study utilized data from the Phase 3 LUCENT induction and maintenance trials for mirikizumab. The modified intent-to-treat (mITT) population, comprising 1281 patients who received at least one dose of mirikizumab or placebo, was analyzed. During induction, patients were randomized in a 3:1 ratio to receive either 300mg mirikizumab intravenously (IV) or placebo every four weeks (Q4W) for 8 weeks. Patients who achieved clinical response (measured by Modified Mayo Score) during induction were then re-randomized in the maintenance phase (2:1 ratio) to receive either 200mg mirikizumab subcutaneously (SC) or placebo Q4W through week 40.

Bowel urgency was assessed using the validated Urgency Numeric Rating Scale (UNRS), where scores range from 0 (no urgency) to 10 (worst possible urgency). A clinically meaningful improvement (CMI) was defined as a reduction of greater than 3 points on the UNRS, and remission was defined as a UNRS score of 0 or 1. Patients recorded their UNRS scores daily via an e-diary, and mean weekly scores were calculated. Comparisons between mirikizumab and placebo groups for BU CMI and BU remission were made at week 12 (induction) and week 40 (maintenance), focusing on patients with a baseline UNRS score of 3 or higher. Statistical analysis employed Cochran-Mantel-Haenszel tests with non-responder imputation for missing data.

Datasets

The study used data from the Phase 3 LUCENT induction and maintenance trials. The modified intent-to-treat (mITT) population included 1281 patients. Specific subgroup analyses for comparisons at week 12 involved 811 patients in the mirikizumab arm and 276 in the placebo arm (baseline UNRS ≥3). For the week 40 maintenance analysis, 336 patients in the mirikizumab arm and 172 in the placebo arm were included (miri induction responders with baseline UNRS ≥3).

Key Insights and Ideas

  • Bowel urgency is a significant unmet need: The paper highlights bowel urgency as a "highly disruptive UC symptom," underscoring its importance beyond other more commonly discussed UC manifestations.
  • UNRS is a sensitive measure: The Urgency Numeric Rating Scale (UNRS) proved to be a useful tool for quantifying both the baseline severity of bowel urgency and the changes observed after treatment, across a range of patient severities.
  • Mirikizumab offers dual benefits: The drug demonstrated efficacy not only in the initial induction phase but also in maintaining these improvements over a longer treatment period.
  • Targeting urgency is crucial for quality of life: By effectively reducing bowel urgency, mirikizumab likely contributes significantly to improving the daily lives and functional capacity of UC patients.

Key Results

In the induction study at week 12, mirikizumab treatment led to significantly higher proportions of patients achieving:

  • Bowel Urgency Clinically Meaningful Improvement (CMI): 48.7% in the mirikizumab group versus 32.2% in the placebo group (p<0.001).
  • Bowel Urgency Remission: 22.1% in the mirikizumab group versus 12.3% in the placebo group (p<0.001).

In the maintenance study at week 40, among mirikizumab induction responders, significantly greater proportions of mirikizumab-treated patients achieved:

  • Bowel Urgency CMI: 65.2% versus 41.9% in the placebo group (p<0.001).
  • Bowel Urgency Remission: 42.9% versus 25.0% in the placebo group (p<0.001).

The baseline UNRS scores were comparable between groups (around 6.1-6.2).

Limitations and Future Work

Limitations: * The paper focuses on a specific subset of patients (those with baseline UNRS ≥3) for the primary comparisons, which is standard for assessing improvement in urgency. However, it's worth noting that the overall mITT population was larger. * The study relies on patient-reported outcomes via an e-diary, which can be subject to recall bias, though the daily recording aims to mitigate this.

Future Work: * The paper implies that further investigation into the long-term impact of mirikizumab on bowel urgency and overall quality of life would be valuable. * Understanding the mechanisms by which mirikizumab specifically targets and alleviates bowel urgency could lead to further therapeutic insights. * Exploring the impact of mirikizumab on bowel urgency in patient subgroups with different disease severities or phenotypes might reveal tailored treatment benefits.

Summary updated

Abstract

Abstract Background Bowel urgency (BU) was assessed in mirikizumab (miri) Phase 3 LUCENT studies in moderately-to-severely active UC using the validated Urgency Numeric Rating Scale (UNRS). UNRS measures BU severity in the past 24 hours from 0 (no urgency) to 10 (worst possible urgency). Psychometric evaluation of the UNRS showed Clinically Meaningful Improvement (CMI) is &amp;gt;3 point change; Remission is a score of 0 or 1. Purpose This analysis evaluated the proportions of patients in LUCENT studies achieving BU CMI and BU remission. Method The modified intent-to-treat (mITT) population (patients receiving ≥1 dose of miri or placebo (PBO); N= 1281) was randomized at induction study baseline in a 3:1 ratio to IV doses of 300mg miri or PBO every 4 weeks (Q4W) during induction (W0, 4, and 8). Patients achieving Clinical Response, measured by Modified Mayo Score (MMS), to miri during induction were re-randomized at W0 of the maintenance study in a 2:1 ratio to subcutaneous (SC) 200mg miri or PBO Q4W through W40 (52 weeks of treatment). Patients recorded their UNRS score daily in an e-diary. Mean weekly UNRS scores were calculated from diary data if ≥4 days of data were available. Rates of BU CMI and BU remission in the miri v PBO groups were compared at W12 (induction) in the mITT population with a baseline UNRS score ≥3, and W52 (maintenance) among miri clinical responders at W12 with a baseline UNRS score ≥3. Cochran-Mantel-Haenszel tests with non-responder imputation for missing values were used for all treatment comparisons. Result(s) Patient population: mean age 43 years, 60% male, disease duration 7 years; 63.0% left-sided colitis; 36.3% pancolitis; 46.7% moderate disease (MMS 4-6); 53.2% severe disease (MMS 7-9). Significantly higher proportions of miri versus PBO patients achieved BU CMI (48.7% v 32.2%) and BU remission (22.1% v 12.3%) at W12 (both p&amp;lt;0.001; Table) in the induction study. Similarly, at W40 of maintenance, significantly greater proportion of miri patients achieved BU CMI (65.2% v 41.9%) and BU remission (42.9% v 25.0%) compared to PBO among miri induction responders (both p&amp;lt;0.001; Table). Image Conclusion(s) Miri had a highly significant and clinically meaningful benefit on reducing bowel urgency, one of the most disruptive UC symptoms. The Urgency Numeric Rating Scale usefully quantified the baseline level and change in bowel urgency after treatment across a spectrum of severity. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Eli Lilly and Company Disclosure of Interest None Declared
BibTeX
@article{travis2023effect,
  author = {Simon Travis and T Hibi and Tadakazu Hisamatsu and Deborah L. Fisher and Mingyang Shan and Theresa Hunter and Donald B. Rubin and Jennifer Jones},
  title = {{A201 EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES}},
  journal = {Journal of the Canadian Association of Gastroenterology},
  year = {2023},
  doi = {10.1093/jcag/gwac036.201},
}
Figure